• LSINW Home Page
• Registration
• Program
• Apply to Present
• Accomodations
• Valued Sponsors
• Sponsor Opportunities
• For Investors
• Poster Session & Speed Dating
• Bio-Partnering
• LSINW Committee
• Volunteers

Platinum Partners:

  

Diamond Partners:

Moss Adams LLP
Davis Wright Tremaine LLP
SightLife

WBBA and Burrill & Company Join Forces to Present: 
Life Science Innovation Northwest Conference 2010

The Washington Biotechnology & Biomedical Association (WBBA) and Burrill & Company are proud to present the region's 10th annual “Life Science Innovation Northwest” conference in Seattle.  Innovation has supercharged the Pacific Northwest’s biotech and medical device industries for decades. Our life sciences companies, non-profit research institutes and global health organizations are leading the way. And, we are pushing forward some of the most compelling technology breakthroughs of our time. As such, this year’s forum—formerly “Invest Northwest”—has been refocused and rebranded to better identify and highlight these unique and powerful assets, defining the Pacific Northwest’s life sciences sector.   See news by Xconomy:  http://www.xconomy.com/seattle/2010/01/29/biotech-bigwig-steve-burrill-brings-national-profile-to-local-conference/

March 16 & 17, 2010
Bell Harbor International Conference Center
Seattle, Washington
 

“Life Science Innovation Northwest will bring public and private life sciences companies, research institutions, scientists, entrepreneurs, and our global health community together to discuss and feature some of the most compelling technology breakthroughs of our time,” said Chris Rivera, President, WBBA. “2009’s meeting was the most widely attended ever, however our partnership with Steve and his team will help extend the reach of the WBBA even further and will broaden the attendee base at this year’s conference. Attendees include; international leaders from public and private investors, investment bankers and industry executives focused on investment and partnering opportunities in life sciences.”

“We are delighted to be associated with the WBBA to stage this event,” said G. Steven Burrill, CEO, Burrill & Company, a San Francisco based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. “The Pacific Northwest region is a vibrant hub for biotechnology and life sciences innovation with all the ingredients for explosive growth – established “blue-chip” companies, world leading research institutions, and a growth venture capital community to invest in early stage companies. “The conference will be a great opportunity to discover and interact with this community first hand."

Attendance Rates

Featured Program Highlights:

• State-of-the-Industry Report by keynote speaker Steven Burrill, Burrill & Company
   
• More than 50 companies presenting companies:  Some of the most innovative organizations, premier research institutions, long-time experts in immunology, oncology and other chronic diseases, pre-emerging and emerging technologies reveal their latest biotech innovations, medical device and diagnostic technologies, global Health initiatives, and bio-fuel and bio-agriculture breakthroughs.
   
• Opportunities to explore financial and strategic investments with China delegation. Travis Sullivan, Director Policy and Strategic Planning for the U.S. Department of Commerce will discuss how the United States and the Pacific Northwest partners with China’s Innovation industries, views green businesses and jobs, as well as the Department of Commerce’s Trade and Promotion.
   
• Strategic and Investment Panels Sessions including:
  • From IP to IPO: Several of the Northwest's public life science CEO's (Seattle Genetics, Dendreon, ZymoGenetics, OncoGeniX and Omeros) discuss the pathway to taking a company public.
  • Public – Private Partnerships, why is industry and global health teaming up? Global health leaders and industry executives will discuss why industry and the global health community are partnering to fight some of our most challenging global health care issues?
  • The VC Model at a Crossroads: Where next? A panel of the nation's leading Venture Capitalists will discuss the future of life science capitalization, moderated by Mark Heesen, President, National Venture Capital Association.
  • Investment or Partnership? What is the best direction for your company? Panelists from leading companies, strategic venture partners, and CEO's from some Northwest companies that have recently partnered with larger companies will discuss the best strategic option in today's economy.
     
• Emerging Company Speed-Dating: Pre-emerging or emerging companies will pitch their ideas and business plans to leading investors.
   
• Poster Sessions: Scientific poster sessions are a fantastic opportunity for pre-emerging companies to share cutting edge innovation with the who's who of life sciences.

About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $950 million under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of leading industry conferences worldwide and publisher of the monthly The Burrill Report (www.burrillreport.com) which tracks the progress of the global biotechnology industry and annual “State of the Industry” report – the 24th edition, Biotech 2010-Life Sciences: Adapting for Success will be available in March. (www.burrillandco.com)